Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: invest04 who wrote (5485)	7/3/1999 3:53:00 PM
From: Arthur Radley	Respond to of 5736

Excuse me! If you had read my post you would see I said...."mentioned IN Barron's". but as you say..."you knew that".

To: invest04 who wrote (5485)	7/5/1999 7:41:00 AM
From: Eddy Blinker	Read Replies (1) \| Respond to of 5736

Belated happy Fourth... In the end they catch all the monkeys. Message 10382624 Regards, ED

To: invest04 who wrote (5485)	7/7/1999 12:29:00 PM
From: JanyBlueEyes	Read Replies (4) \| Respond to of 5736

News - CCSI Responds to Inaccurate Article in Barrons Chromatics Color Sciences Responds to Inaccurate Comments Reported in Barron's NEW YORK, July 7 /PRNewswire/ -- Chromatics Color Sciences International (Nasdaq: CCSI) issued the following today: Last month, Chromatics Color Sciences signed an agreement with a major medical product distributor for the marketing and distribution of its Colormate(R) TLc-BiliTest(TM) System -- a device that represents a true breakthrough in the pain-free monitoring of infant jaundice. This came after CCSI successfully exhibited the System at medical conferences around the world, obtained vital international ISO9000 quality and safety certifications, successfully tested the System in several major hospitals and commenced mass manufacturing. Details of the above have been provided in previous public statements by the Company and in public filings including the Form 8-K filed on June 18, 1999. In the July 5, 1999 edition of Barron's, however, a Thomas Claugus is attributed with false and misleading statements about the development, testing, regulatory clearance and use of the System; providing a self-serving underestimate of the potential size of the market; and making an irrelevant comparison with another product that does not appear to have a comparable range of applications. Among Mr. Claugus' most blatant falsehoods: -- A statement that CCSI received FDA clearance for its product without being tested against blood analysis. This is false -- the Colormate(R) Bili-Test(TM) System was tested versus traditional blood testing with a high correlation not only for FDA clearance purposes, but also for peer review and publication by the American Academy of Pediatrics. This has been repeatedly disclosed in the Company's news releases and other public statements over the past two years. -- An indication that CCSI stock dropped at some point due to a termination of its business relationship with Avon. The CCSI-Avon contractual relationship ended well before CCSI went public in 1993. The stock price did drop in mid 1998, due to a concerted short-selling attack that relied on the same type of falsehoods contained in Mr. Claugus' published comments. The actual steady stream of significant good news regarding CCSI during the past year shows a company and a product well-positioned for the future -- notwithstanding false commentary to the contrary. Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties that it believes have medical applications involving monitoring of certain chromogenic diseases or disorders such as hyperbilirubinemia in newborns. The Company defines chromogenic diseases or disorders as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. Additional medical applications to the monitoring of hyperbilirubinemia in newborns will require additional clinical trials and FDA clearances for commercial use. The Company's technologies and intellectual properties also have other applications including the scientific color measurement and classification of human skin and certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty-aid and fashion industries. Certain of the matters discussed in this announcement contain forward-looking ..... SOURCE Chromatics Color Sciences International, Inc. CONTACT: Darby Macfarlane, Chief Executive Officer of Chromatics Color Sciences, 212-717-6544; or Rick Matthews of Rubenstein Associates Public Relations, 212-843-8007, for Chromatics Color Sciences/